Benchmark Holdings (FRA:31B) Research & Development: €0.63 Mil (TTM As of Mar. 2025)


FRA:31B Benchmark Holdings PLC FRA:31B
30 GF Score
Price €0.24
View Full Analysis

What is Benchmark Holdings Research & Development?

Benchmark Holdings FRA:31B 30 Research & Development is €0.63 Mil as of Mar. 2025. GuruFocus rates FRA:31B with a GF Score™ of 30/100.

Research & Development is the aggregate amount of research and development expenses during the year. Benchmark Holdings's Research & Development for the three months ended in Mar. 2025 was €0.70 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 was €0.63 Mil.

Benchmark Holdings  (FRA:31B) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Benchmark Holdings Research & Development Related Terms

Benchmark Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for Benchmark Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Benchmark Holdings Research & Development Chart

Benchmark Holdings Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.01 8.19 7.59 2.73 2.91

Benchmark Holdings Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.68 1.67 -2.41 0.69 0.70
FRA:31B
30GF Score
Benchmark Holdings PLC FRA:31B
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Benchmark Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.63 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.63 Mil mean?
Benchmark Holdings (FRA:31B) has a Research & Development of €0.63 Mil as of Mar. 2025. Research and development expense is the total cost for research and development activities. View historical data on Benchmark Holdings and its competitors.
Is Benchmark Holdings' Research & Development too high?
Benchmark Holdings' current Research & Development is €0.63 Mil. Overall, Benchmark Holdings has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Benchmark Holdings' Research & Development compare to JBS and KHC?
Benchmark Holdings' Research & Development of €0.63 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Consumer Packaged Goods company?
A good Research & Development depends on the Consumer Packaged Goods industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Benchmark Holdings and its competitors. Benchmark Holdings's current Research & Development is €0.63 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Benchmark Holdings stock overvalued right now?
Benchmark Holdings (FRA:31B) has a current Research & Development of €0.63 Mil. The current Research & Development is €0.63 Mil. Benchmark Holdings' overall GF Score™ is 30/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Benchmark Holdings (FRA:31B), the current Research & Development is €0.63 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Benchmark Holdings Business Description

Address Yeoman Way, Benchmark House, Highdown House, West Sussex, Worthing, Sussex, GBR, BN99 3HH
Benchmark Holdings PLC offers products and solutions that improve farming efficiency, growth, and animal health and welfare for aquaculture producers. Its portfolio of products and solutions includes salmon eggs, live feed (artemia), diets and probiotics, sea lice treatments, and others. The company's reportable segments are; Genetics, Advanced Nutrition, and Health. Maximum revenue for the company is generated from its Advanced Nutrition segment which manufactures and provides nutrition and health products to the aquaculture industry. The Health segment focuses on providing health products to the aquaculture market. Geographically, the company derives its maximum revenue from Norway and the rest from Chile, Iceland, Canada, Greece, China, the United Kingdom, and other markets.
30GF Score

Get the complete analysis for FRA:31B

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.24
Price